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Abstract
Background: To validate the ‘Test of Adherence to Inhalers’ (TAI), a 12-item questionnaire designed to assess
the adherence to inhalers in patients with COPD or asthma.
Methods: A total of 1009 patients with asthma or COPD participated in a cross-sectional multicenter study.
Patients with electronic adherence ‡80% were defined as adherents. Construct validity, internal validity, and
criterion validity were evaluated. Self-reported adherence was compared with the Morisky-Green questionnaire.
Results: Factor analysis study demonstrated two factors, factor 1 was coincident with TAI patient domain (items 1
to 10) and factor 2 with TAI health-care professional domain (items 11 and 12). The Cronbach’s alpha was 0.860
and the test-retest reliability 0.883. TAI scores correlated with electronic adherence (q¼0.293, p¼0.01). According
to the best cut-off for 10 items (score 50, area under the ROC curve 0.7), 569 (62.5%) patients were classified as non-
adherents. The non-adherence behavior pattern was: erratic 527 (57.9%), deliberate 375 (41.2%), and unwitting 242
(26.6%) patients. As compared to Morisky-Green test, TAI showed better psychometric properties.
Conclusions: The TAI is a reliable and homogeneous questionnaire to identify easily non-adherence and to
classify from a clinical perspective the barriers related to the use of inhalers in asthma and COPD.
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Introduction
It has been estimated that the degree of compliancewith inhaled drug therapy in patients with asthma and
chronic obstructive pulmonary disease (COPD) does not
surpass 50%.(1,2) In these patients, non-adherence or inhaler
mishandling increases mortality, morbidity, and health care
resource utilization.(3–6) Factors related to adherence with
inhaled therapy include complexity of the inhalation regimen,
peculiarities of inhaler devices, type of inhaled agent, and a
variety of patient beliefs and sociocultural and psychological
factors.(7) Therefore, promoting optimal medication adher-
ence is essential to optimize the benefits of treatment. Con-
sequently, measurement of the degree of adherence to inhaled
treatment in each individual patient becomes increasingly
important in daily practice.
Adherence to medication is mainly assessed by direct an-
amnesis with the patient, which invariably underestimates the
incidence of non-adherence rates. Although standardized
patient self-completed questionnaires for measuring medi-
cation adherence have been developed,(8–10) its real use in
clinical practice is scarce. Moreover, some features make
them inappropriate because they are not adequately validated,
not specific for inhaler devices,(8–10) or only applicable to
certain patient populations (asthmatics) or particular inhaled
agents (corticosteroids).(10)
A further limitation of these questionnaires is a doubtful
clinical usefulness to identify barriers to medication adher-
ence and patients at risk of non-adherence. Non-adherent
behavior has been broadly classified as erratic, deliberate, and
unwitting non-adherence.(11,12) Up to the present time, how-
ever, these typologies have not been reflected in any particular
instrument to assess adherence to inhaled therapy. Knowl-
edge of behavior patterns of non-adherence and, particularly,
barriers to treatment adherence is clinically relevant to deliver
tailored patient education strategies.
With the objective to provide a new questionnaire specif-
ically designed to establish self-reported adherence to inhaler
devices and to help clinicians to assess non-adherence barri-
ers related to inhaled therapy in adult asthma and COPD pa-
tients, we developed the Test of Adherence to Inhalers (TAI).
Initially, a multidisciplinary panel of health care profession-
als involved in respiratory diseases built, in a pilot study, a test
draft version with 12-items. The aim of this study was to
validate and to evaluate the psychometric properties of the
proposed 12-item TAI.
Materials and Methods
Development, domains, items, and scores of the TAI
The TAI was developed in Spanish and was built in three
phases. First, the items that made the first version of the ques-
tionnaire were derived from a review of the literature (8,11,13)
and suggestions of the study scientific committee, which lead
to a preliminary version that was tested in a group of 10
patients with asthma and/or COPD patients in order to check
the intelligibility of the questionnaire. In the second phase,
a multidisciplinary panel of 192 investigators composed
by pulmonologists, allergists, primary care physicians, and
specialized nurses worked together in order to reach a con-
sensus on the items to be included in the questionnaire (based
on the Delphi method).(14) In the third phase, a pilot study was
performed with the aim to produce a final version (beta ver-
sion) of the TAI, prior to the validation study.
The final version of the questionnaire included 12 items
(Table 1) with two main domains, the patient (items #1 to #10)
and the health professional (items #11 and #12) domain. In fact,
the TAI consists of two complementary questionnaires: the 10-
items TAI was designed to identify non-adherent patients and
to establish the non-adherence level, whereas the 12-items TAI
was designed to guide clinically the non-adherence patterns.
In the 10-items TAI, each item scored from 1 to 5 (where 1
was the worst possible score and 5 was the best possible score),
with a range from 10 to 50. The 12-items TAI, also includes
items #11 and #12 of the health care professional and scored as 1
or 2 (where 1 was bad and 2 was good), with a range from 2 to 4.
The latter items were designed to identify two possible causes of
unwitting non-adherent behavior. An erratic and deliberate non-
adherent behavioral pattern was defined in the presence of
scores £ 24 for items #1 to #5 and items #6 to #10, respectively.
The unwitting pattern was defined in the presence of a score 1 in
at least one of the #11 or #12 items of the questionnaire.
In the pilot study, the questionnaire was fulfilled by 50
patients (29 patients with asthma and 21 with COPD),
showing a kappa index of 0.858 between independent ob-
servers for items #11 and #12.
Study design and participants
Between March 2013 and March 2014, a cross-sectional
multicenter study was conducted to validate the TAI instru-
ment. Eligible patients were Spanish speaking men and wo-
men, over 18 years of age, treated with inhaled medications for
at least 6 months before enrolment. Subjects were consecu-
tively enrolled from the outpatient visits of the participant
centers. Patients with inability to fulfill the questionnaire and/
or to use inhaler devices were excluded. Asthma and COPD
were defined according to the respective current international
guidelines.(15,16) A total of 194 investigators from 139 pul-
monology, allergology, and primary care centers participated
in the study.
The control group (electronic adherence group) was made
up of smartphone user patients with asthma using electronic
inhaler devices (Smart-inhalers) (Nexus6 Ltd., Auckland,
New Zealand), which silently recorded the date and time of
each actuation.(17) These patients were participating in an
ongoing study aimed to assess asthma control using electronic
medication monitoring, and also were consecutively enrolled
from the outpatient visits of the same participating centers.
For the purpose of the present study, the inhaler device used
(pressurized metered dose inhaler, pMDI, Turbohaler or
Diskus) was connected to a specific smart-inhaler.
The study was approved by the Clinical Research Ethics
Committee (registration number 2013/8650) of the Hospital
Clinic of Barcelona (Spain). Written informed consent was
obtained from all participants.
Study procedures
A flow-chart of the study procedures is shown in Figure 1.
All study participants attended two consecutive clinical
visits 15 days apart. At visit 1, written informed consent was
obtained and data on demographics, sociocultural level, and
asthma or COPD history were recorded. Also, all patients
completed a validated Spanish version of the Morisky-Green
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test,(8,9) and the TAI questionnaire administered. Informa-
tion related to the feasibility of the TAI was also collected,
such as the time needed to complete the questionnaire and if
complementary explanations to understand the questions of
the items were required.
Clinical asthma control was assessed with the Asthma
Control Test (ACT)(18,19) (an ACT score ‡20 identified
well-controlled asthma patients), and COPD clinical status
was evaluated with the COPD Assessment Test (CAT)(20)
(CAT £10 identified mild COPD patients). Spirometry was
performed according to the European Respiratory Society/
American Thoracic Society guidelines(21) using the pre-
dicted values for Mediterranean population.(22) At visit 2,
the Morisky-Green test and TAI were also administered.
Patients in the electronic adherence group also completed
the Morisky-Green test and the TAI questionnaire. In these
patients, the main measure of electronic adherence was the
percentage of inhalations performed correctly between visits
1 and 2. Patients were defined as adherents when ‡80% of the
doses prescribed were taken, intermediate adherent when
took between 50% and 80%, and non-adherent when took
£50%.(10,23) To correct the bias related to a possible error in
handling of the electronic inhaler being a new device, the first
two actuations recorded were not included in the analysis.
Adherence rates were capped at 100% to avoid dump doses
or unintentional actuation.(13)
Sample size calculation and statistical analysis
The sample size was calculated to detect small differ-
ences in the TAI scores between visits 1 and 2. Thus, ac-
cepting a significance level of 5% and a power of 80%, 870
patients were required to detect differences ‡0.2 standard
deviations in scores between the two administrations of the
questionnaire. A 10% percentage of patients lost to follow-
up or with incomplete data were established.
Categorical variables are expressed as absolute and relative
frequencies and percentages, and quantitative variables as mean
and standard deviation (SD) or median and range (minimum,
maximum). To assess the construct validity of the technique of
principal component factor analysis with Varimax rotation was
used to identify chasing one-dimensional or multidimensional
structure of the questionnaire. The appropriateness of factor
analysis was verified by measurement of Kaiser-Meyer-Olkin
(KMO)(24,25) and Bartlett’s test of sphericity.(26) Internal reli-
ability was measured with the Cronbach’s alpha coefficient.(27)
The test-retest reliability of the questionnaire was analyzed
using the intraclass correlation coefficient (ICC).28 The
Table 1. Description of Test of the Adherence to Inhalers (TAI) Questionnaire
Patient domain: questions, responses (scores) Score
1. During the last 7 days, how many times did you forget to take your usual inhalers?
All (1) More than half (2) Approximately a half (3) Less than half (4) None (5) 1 to 5
2. Do you forget to take inhalers?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
3. When you feel good about your illness, do you stop taking your inhalers?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to5
4. When you are on vacation or weekend, do you stop taking your inhalers?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
5. When you are nervous or sad, do you stop taking your inhalers?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
6. Do you stop taking your inhalers because of fear of side effects?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
7. Do you stop taking your inhalers because of considering they are useless to treat your condition?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
8. Do you take fewer inhalations than those prescribed by your doctor?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
9. Do you stop taking your inhalers because you believe they interfere with your everyday or working life?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
10. Do you stop taking your inhalers because you have difficulties to pay them?
Always (1) Mostly (2) Sometimes (3) Rarely (4) Never (5) 1 to 5
Health care professional domain: questions, responses (scores)
11. Does the patient remember the prescribed regimen (dose and frequency)? (checking the medical record)
No (1) Yes (2) 1 or 2
12. The technique of using the evaluated inhaler device by the patient is* (checking the inhalation technique)
With critical mistakes (1) Without critical mistakes (2) 1 or 2
*Critical mistakes: 1. Pressure metered dose inhalers (pMDIs): do not remove the cover, do not hold the inhaler in a vertical position,
firing the device before beginning inspiration, inhalation stopped, inhalation too fast, incorrect insertion of MDI into the inhaler camera,
several device firing in the same inhalation, no breath hold after inhalation, cough during inhalation. 2. Dry power inhalers (DPIs): do not
open the inhaler, do not prime properly, place the device down after preparation of the dose (before inhalation), blow into the device before
inhalation, inhalation not deeply and forcefully, no breath hold after inhalation.
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criterion validity was made by comparing the percentage of
electronic adherence with self-adherence reported in the TAI
score. Sensitivity, specificity, positive and negative predictive
values were calculated. Cut-offs of the most favorable bal-
ance between sensitivity and specificity with the corre-
sponding received operating characteristics (ROC) curves and
the area under the curve (AUC) were determined. The Mann-
Whitney U test was used for the comparison of quantitative
variables and the chi-square (v2) test for categorical variables.
Correlation between two measures was assessed with the
Spearman’s rank-order correlation coefficient (q). Statistical
analysis was performed with Statistical Package for the So-
cial Sciences (SPSS, Chicago, IL, USA) (version 17.0 for
Windows). Statistical significance was set at p< 0.05.
Results
Characteristics of the study population
A total of 910 patients were included in the self-reported
adherence group (500 asthma and 410 COPD) and 99
asthma patients in the electronic adherence group. Socio-
demographic data, clinical features and results of pulmonary
function tests are shown in Table 2. Patients in both groups
were not comparable given that patients in the electronic
adherence group were asthmatics, with a higher proportion
of women, younger age, better education level and lung
function. However, patients with asthma in the self-reported
and electronic adherence groups were similar except for a
higher percentage of never smokers (70.8% vs. 58.6%,
p = 0.016) and patients who received previous inhaler edu-
cation (79.5% vs. 63.9%, p = 0.001) in the self-reported
adherence group. Differences according to age strata or
education level were not found.
Psychometric properties of TAI
Scores of the two domains (patient and health care pro-
fessional) of the TAI are shown in Table 3. The electronic
adherence group scores were significantly higher than the
self-reported adherence group in the patient domain.
Sampling adequacy for factor analysis assessed with the
KMO and the Bartlett’s test was appropriate, with a coefficient
of 0.905. Factor analysis showed a probable structure of two
factors, which explained 51% of the total variance of results.
The first factor included items #1 to #10, which was consistent
with the patient domain, and the second factor included items
#11 and #12 in agreement with the health care professional
domain (see Supplementary Table S1; supplementary material
is available online at www.liebertpub.com/jamp).
Internal reliability of TAI showed a good inter-item corre-
lation with a Cronbach’s alpha coefficient of 0.873 for the 10-
items patient domain. The test–retest reliability showed an ICC
of 0.883. The mean time needed to fulfill the questionnaire was
6 (5.3) minutes. A total of 151 (15%) patients required sup-
plementary clarifications to complete the patient domain.
In the electronic adherence group, 46 (46.5%) patients
were classified as adherents and the remaining 53 (53.5%) as
non-adherents. Adherent patients as compared with non-
adherent patients showed slightly higher scores in the 10-items
patient domain score (48.5 [3.0] vs. 46.8 [4.0]. These differ-
ences were statistically significant (p= 0.02). In relation to the
criterion validity, TAI scores correlated with electronic ad-
herence for the 10-items TAI scores (q=0.286, P=0.01).
FIG. 1. Flow-chart of the study design and procedures.
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Classification of adherence levels
with the 10-items TAI
The sensitivity, specificity, and positive and negative pre-
dictive values of the 10-items TAI scores for identifying the
groups of adherent, intermediate adherent and non-adherent
patients are shown in Table 4. Cut-offs with the most fa-
vorable balance between sensitivity and specificity were 50
for adherent patients, 46 to 49 for intermediate adherent pa-
tients, and £45 for non-adherent patients. The ROC curves for
the groups of adherent and non-adherent patients are shown
in Figure 2. The percentages of adherent patients were sig-
nificantly higher in the electronic adherence group than in the
self-reported adherence group (49.5% vs. 37.5%, p= 0.02) but
the distribution of intermediate adherent patients was similar.
The rates of non-adherence were also higher in the self-
reported adherence group (Fig. 3). A good correlation (q=
0.3, p= 0.01) was found when adherence levels between
self-reported and electronic adherence groups were compared.
Clinically guide of the non-adherence behavior
patterns with the 12-items TAI
The 12-items TAI instrument allowed the classification of
three non-adherence patterns. In both groups of self-reported
and electronic adherence, erratic behavior was the most
Table 2. Sociodemographic, Clinical Characteristics, and Spirometric Data
Self-reported adherence
group (n = 910)
Data
All
patients
COPD
(n = 410)
Asthma
(n = 500)
Electronic
adherence
group (n = 99) P value*
Men 510 (56.0) 340 (82.9) 170 (34.0) 32 (32.3) 0.747
Age, years 58.0 (16.3) 67.8 (9.6) 49.9 (16.3) 47.8 (17.8) 0.209
Education level
No studies 71 (7.8) 52 (12.7) 19 (3.8) 2 (2.0) 0.224
Primary education 416 (45.7) 240 (58.5) 176 (35.2) 26 (26.3)
Secondary education 249 (27.4) 76 (18.5) 173 (34.6) 42 (42.4)
University degree 174 (19.1) 42 (10.2) 132 (26.4) 29 (29.3)
Clinical data
Smoking history
Current smoker 128 (14.1) 91 (22.2) 37 (7.4) 6 (6.1) 0.016
Ex-smoker 414 (45.5) 305 (74.4) 109 (21.8) 35 (35.4)
Never smoker 368 (40.4) 14 (3.4) 354 (70.8) 58 (58.6)
Duration of disease, years 13.5 (10.6) 10.5 (8.2) 16.0 (11.6) 17.9 (12.3) 0.151
Previous inhaler education 690 (80.0) 310 (80.5) 380 (79.5) 62 (63.9) 0.001
Asthma Control Test (ACT) ‡20 289 (57.8) NA 289 (57.8) 66 (66.7) 0.257
COPD assessment test (CAT) £10 91 (22.2) 91 (22.2) NA NA
Pulmonary function tests
FEV1 prior to bronchodilator test, mL 2026 (982.8) 1587 (924.1) 2.380.7 (881.3) 2434.9 (981.3) 0.718
FEV1 prior to bronchodilator test, % 68.5 (24.5) 52.0 (18.3) 81.8 (20.5) 79.6 (20.6) 0.432
FEV1 after bronchodilator test, mL 2123.4 (960.4) 1571.4 (732.8) 2574.5 (886.2) 2548 (919.4) 0.832
FEV1 after bronchodilator test, % 74.0 (26.4) 55.9 (20.1) 88.7 (21.3) 86.3 (19.4) 0.211
*Comparison between asthma patients in the self-reported and electronic adherence groups. Data as frequencies and percentages in
parentheses unless otherwise stated.
Table 3. TAI Scores in the Study Population
Study groups
Patient
domain
score
(items #1
to #10)
Health care
professional
domain score
(items #11
and #12)
Self-reported adherence group (n = 910)
Mean (SD) 46.1 (5.2) 3.7 (0.6)
Median (minimum;
maximum)
48 (18; 50) 4 (2; 4)
Electronic adherence group (n = 99)
Mean (SD) 47.6 (3.7) 3.8 (0.4)
Median (minimum;
maximum)
49 (30; 50) 4 (2; 4)
P value* 0.005 0.084
*Comparison between self-reported and electronic adherence
groups.
Table 4. Sensitivity, Specificity, and Predictive
Values of the Different Cut-offs
of the 10-Items TAI Score
Predictive value
Cut-offs
TAI scores*
Sensitivity
(%)
Specificity
(%)
Positive
(%)
Negative
(%)
50 67.4 66.0 63.3 70.0
49 78.3 50.9 58.1 73.0
48 80.4 43.3 55.2 71.9
47 84.8 30.2 51.3 69.6
46 84.8 26.4 50.0 66.7
45 84.8 22.6 48.8 63.2
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frequent, followed by deliberate and unwitting behaviors
(Table 5).
Comparison between TAI and the Morisky-Green test
As compared to the Morisky-Green test, TAI showed a
slightly better psychometric parameters, with a q = 0.286 for
the correlation between 10-items TAI scores and Smart-
inhalers records of the electronic group patients, and a
q = 0.247 for the correlation between Smart-inhalers re-
cords of the electronic group patients and the Morisky-
Green test scores. The kappa statistics was 0.33 for the
10-items of the TAI questionnaire and 0.28 for the Morisky-
Green test. Regarding the ability to identify adherent and
non-adherent patients, the 10-items TAI showed an in-
termediate position between the rates observed with the
Smart-inhaler electronic devices and the Morisky-Green test
(Table 6).
FIG. 2. ROC curves for the classification of adherent (AUC=0.7) and non-adherent (AUC=
0.6) patients using a cut-off of the 10-items TAI questionnaire of 50 and £45, respectively.
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Discussion
This study shows the validity of a new questionnaire to
assess adherence to inhaled medication in patients with asthma
or COPD. The TAI instrument possesses good psychomet-
ric properties and has been shown not only to be adequate
to classify asthma and COPD patients as adherent or non-
adherent to inhaled therapy, but also to recognize the pre-
dominant pattern of non-adherence behavior in individual
patients. Moreover, the questionnaire is short and easy to use
for patients of different ages and education levels, providing a
cheap, quick, and efficient way of obtaining information on
inhaler adherence and non-adherence patterns, applicable to
daily practice.
In the present study using a valid qualitative methodology,
a total of 12 conditions or barriers to the use of inhalers,
which have been related to the control of respiratory diseases
in previous studies,(29–32) were formed by a consensus of a
large group of health care professionals and thereupon, in a
large sample of patients. Questionnaires available up to
date(8–10,29) have also assessed some conditions included in
the TAI, although in a partial way including forgetfulness,
lack of need of inhaler use, side effects-related concern and
availability of the inhaler. However, none of these single
barriers has shown predictive validity in the adherence to
inhalers.
Since TAI in the extent that covers a wider range of
situations (in comparison to its predecessors) and has been
shown its viability in the health care setting, it may be a
valuable tool for clinical use. Also, a novel aspect of the
questionnaire is the inclusion of health care professionals’
assessment of the patient’s ability with the use of his/her
inhaler. The patient competence in handling the device is a
prerequisite for adherence. Therefore, based on the meth-
odology used in the development of the TAI, the 12 con-
ditions assessed by the instrument are clinically relevant to
determine the level of adherence to inhalers.
The large study population of patients with COPD and
asthma recruited by almost 200 specialists in different health
care settings allowed a study of a representative sample of
the patients with asthma and COPD, their treatment, and,
therefore the main barriers modulating patient–physician
FIG. 3. Overall adherent and non-adherent percentages of patients and adherence levels in the
self-reported (n=901) and electronic (n=99) adherence groups with the 10-items TAI.
Table 5. Non-adherence Behavior Patterns
Oriented with the 12-items TAI
Non-adherence
pattern*
Self-reported
adherence
group (n = 910)
Electronic
adherence
group (n = 99)
Erratic 530 (58.2) 48 (48.5)
Deliberate 376 (41.3) 26 (26.3)
Unwitting 242 (26.6) 19 (19.2)
*Frequency of non-adherent patterns is higher than 100% because
more than one non-adherent pattern may be present in the same
patient.
Table 6. Ability to Identify Adherent and
Non-adherent Patients with Smart-Inhaler
Device, 10-Items TAI, and Morisky-Green
Test in Electronic Adherence Group
Smart-inhaler
electronic
device
10-items
TAI
questionnaire
Morisky-
Green
test
Adherent
patients, n (%)
46 (46.5) 49 (49.5) 52 (52.5)
Non-adherent
patients, n (%)
53 (53.5) 50 (50.5) 47 (47.5)
Total patients 99 99 99
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relationship, satisfaction, and health care system functioning
that may affect adherence. Accordingly, the study sample
was adequate to assess adherence to inhalers in both dis-
eases from an overall perspective.
On the other hand, the inclusion of electronic devices
provided reliable data on adherence in a group of partici-
pants. This objective measure of adherence, which is un-
usual in validation studies of other questionnaires probably
because of the high cost, guaranteed robustness of the val-
idation process. Scores of the 10-items and 12-items TAI
were directly and positively correlated with data recorded
with the Smart-inhalers, and differences between patients
classified as adherents and non-adherents were also statis-
tically significant. The observation that correlations, al-
though statistically significant, were somewhat low may be
explained by the fact that self-reported adherence is less
reliable than electronic measures,(33) and the lower sample
size in the electronic adherence group which probably pre-
vented to achieve better correlation levels.
The differences in sociodemographic and clinical charac-
teristics between patients in the electronic adherence group
(higher percentage of women and education level) and the self-
reported adherence group (combination of asthma and COPD
patients, with a lower percentage of women and education
level) do not question the validation of TAI. Results obtained in
the electronic adherence group will be potentially generaliz-
able to a similar population and also be subjected to similar
adherence-related difficulties or barriers. It is possible that
clinical and sociodemographic characteristics of the electronic
adherence group may be the reason for significantly better TAI
scores in this group as compared to the self-reported adherence
group. Also, the large number of patients in the self-report
adherence group versus the electronic adherence group prob-
ably determined that statistical significance could be easily
reached. Despite these considerations, findings in the elec-
tronic adherence group provide solid evidence of the capacity
of TAI to identify adherence to inhalers.
In relation to the electronic device monitoring, it should be
noted that information recorded by the electronic devices not
only includes whether the patient used the inhaler for a certain
number of times, but also the hours at which the device was
used during the ‘‘evaluation’’ days (in our study the 14 days
between visits 1 and 2). This eliminates the possibility of
dumping occurring immediately prior to the control visit be-
cause it would be registered that the patient used the inhaler on
multiple occasions in that day and not in the expected mode
(several times during the 14 days period). On the other hand,
first readings of smart-inhalers on visit 1 were discarded to
exclude the possible impact of the patient’s training effect.
According to factor analysis of the two main components,
different criteria for scoring these two dimensions were chosen.
Clinical practice experience and the results of numerous
studies34,35 indicate that knowledge/recall of the prescription
(item #11) and competence in using the inhaler (item #12) are
prerequisites for adherence. Consequently, they play a differ-
ential role in adherence-related barriers, which logically also
appeared statistically as a differential factor. This finding
suggests that TAI may be used as a questionnaire of two
measures with different applications: to identify adherence
(10-items TAI, patient domain) and to have a clinical indica-
tion of the non-adherence behavior pattern (12-items TAI, both
patient and health care professional domains).
The unidimensional structure of the 10-items TAI reflects
the complexity of the adherence phenomenon. Studies in pa-
tients with respiratory disorders and other diseases36,37 have
shown that adherence is a particular complex issue, in which
different barriers that compromise adherence have a low pre-
dictive capacity by themselves but combine and modify during
the process of disease. In this respect, results of the present
study show that when patients are classified by responses
suggesting an erratic, deliberate, or unwitting non-adherence
behavior pattern, the possibility to identify statistically differ-
ent types of non-adherent patients was compromised.
This consideration, however, does not affect the internal
validity of the instrument or the clinical usefulness of TAI. On
the contrary, the percentages of non-adherence regarding the
total number of items as well as grouped by the profile of non-
adherence are sufficiently indicative of the importance of the
problem and the value of the qualitative analysis of the items of
each of the three non-adherence behaviour pattern. Accord-
ingly, it is possible to identify quickly, reliably and objectively
situations that may compromise adherence to inhaler devices
that might otherwise go unnoticed in routine clinical practice.
There are some limitations of the study that deserves a
comment. First, the lack of an electronic control group for
COPD patients. Second, the weight of each adherence-related
barrier according to different clinical and sociodemographic
characteristics of patients with respiratory diseases and the
inter-relationship among barriers were not assessed. Internal
validity and clinical relevance of the study, however, are not
affected by these limitations. In further studies, the Rash model
approach as used by Kleppe et al.(38) in the development of a
Probabilistic Medication Adherence Scale (ProMAS) tested in
370 elderly patients receiving medication for chronic condi-
tions may be suggested to assess the construct validity of TAI.
In conclusion, TAI is a new questionnaire, specifically
developed to identify non-adherence and specific adherence
barriers involved in inhaled therapy. The study demonstrated
the good psychometric properties of the questionnaire and
validated their usefulness in the clinical setting. This could
bring a new tool, to improve the patient’s adherence to in-
haler devices, according to their specific non-adherence pat-
tern after implement tailored strategies.
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